Therapeutic targets for improving intramural periarterial drainage (IPAD) in the prevention and treatment of cerebral amyloid angiopathy (CAA) and Alzheimer’s disease
R. Carare 2017, R.O.Carare@soton.ac.uk
Intramural periarterial drainage (IPAD) of fluid and soluble peptides from the brain parenchyma occurs along the basement membranes of cerebral capillaries and arteries, against the direction of blood flow and towards the leptomeningeal arteries (1). Failure of IPAD with increasing age is associated with the failure of elimination of Aβ from the brain, CAA and Alzheimer’s disease. Genetic mutations involving amyloidogenic peptides, such as Aβ and Cystatin, also result in CAA.
Experimentally, IPAD is impaired in [a] aged mice, [b] in the presence of CAA, [c] in mice with human apolipoprotein E4 genotype, [d] in mice with hyperlipidemia associated with maternal high fat diet during gestation, and [e] in mice associated with the formation of immune complexes in IPAD pathways (2)(3)(4)(5)(6)(7). Changes in the extracellular matrix within artery walls are reflected in the structural, morphological and biochemical modifications of the vascular basement membranes and are associated with CAA (8)(9).
Although the driving force for IPAD was originally thought to be derived from the pulsations from the heart, the biophysical properties of the pulse wave are not adequate for efficient IPAD (10). Instead, recent mathematical modelling demonstrates that the contraction of smooth muscle cells in the walls of cerebral arterioles, and possibly of pericytes in the walls of capillaries, would generate a process termed vasomotion of the appropriate amplitude and wavelength to provide the motive force for IPAD (Aldea R, PhD thesis submitted Nov 2017, manuscript in preparation).
The observations from human CAA and from experimental studies of those factors that impair IPAD suggest two major therapeutic strategies may prevent or ameliorate CAA and Alzheimer’s disease: [a] Maintaining the tone of artery walls: [b] Preventing and retarding the onset of arteriosclerosis. Age changes and arteriosclerosis weaken contraction of intramural cells, particularly smooth muscle cells in the tunica media of arteries, and also induced changes in the extracellular matrix, particularly the basement membranes of smooth muscle cells that form the IPAD pathway. Preventing age changes in the walls of arteries, stimulating smooth muscle cell contraction and improving IPAD are promising strategies for the prevention of CAA and Alzheimer’s disease.
Strategies for improving IPAD
Agents that improve contractility of vascular smooth muscle cells: Phosphodiesterase III is the major cAMP-hydrolyzing PDE uniquely expressed in vascular smooth muscle cells; PDE IIIA isoforms are also involved in cardiovascular function by regulating vascular smooth muscle growth and phenotypic changes. Cilostazol is a selective inhibitor of PDE III that increases cAMP in vascular cells and has multiple effects on the vasculature such as vasodilatation, anti-oxidation, anti-inflammation, regulation of smooth muscle cells, increase in cerebral haemodynamics and arterial elasticity with maintenance of microvascular integrity, as reviewed in (11). Cognition is significantly improved in experimental models and in humans receiving Cilostazol (12)(13)(14)(15). Administration of Cilostazol significantly improves IPAD and the brains of mice treated with Cilostazol show effects upon extracellular matrix, with upregulation of the anti-fibrillogenic glycoproteins (16)(17).
Using chaperones for efficient transport along the IPAD pathways: Clusterin (Apolipoprotein J) is a multifunctional protein that reduces the aggregation and toxicity of Aβ and appears to be beneficial in atherosclerosis (18)(19). We recently demonstrated that in APP/PS1 mouse models of Alzheimer’s disease, crossed with clusterin knockout mice, result in disappearance of Aβ plaques but an increase in severity of CAA. These findings suggest that clusterin is required for efficient chaperoning of solubilized proteins from plaques along IPAD (20). Administration of clusterin as a preventative therapy when the integrity and function of smooth muscle cells and basement membranes are not compromised may yield positive results for the prevention or delay in onset of symptoms of CAA and Alzheimer’s disease. Taxifolin is flavonoid that appears to maintain amyloid in its soluble forms more amenable for clearance (21). We are investigating whether Taxifolin facilitates IPAD.
Agents acting upon the innervation of smooth muscle cells: Experimental work is ongoing in this area. Results suggest that agents such as Prazosin, an alpha(1)-adrenoceptor antagonist, acting upon cholinergic or adrenergic innervation of cerebral arteries result in improvements of IPAD and in reduction of CAA in transgenic mouse models of Alzheimer’s disease (22).
Morris A, Sharp M, Albargothy N, Fernandes R, Hawkes C, Verma A, et al. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. 2016 Mar 14;131:725–36. [PMC]
Hawkes C, Gatherer M, Sharp M, Dorr A, Yuen H, Kalaria R, et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain. Aging Cell. 2013 Apr 1;12(2):224–36. [PubMed]
Hawkes C, Sullivan P, Hands S, Weller R, Nicoll J, Carare R. Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One. 2012 Jan 1;7(7):e41636. [PubMed]
Hawkes C, Gentleman S, Nicoll J, Carare R. Prenatal high-fat diet alters the cerebrovasculature and clearance of β-amyloid in adult offspring. J Pathol. 2015 Mar 1;235(4):619–31. [PubMed]
Carare R, Teeling J, Hawkes C, Püntener U, Weller R, Nicoll J, et al. Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer’s disease. Acta Neuropathol Commun. 2013 Aug 9;1:48. [PubMed]
Hawkes C, Härtig W, Kacza J, Schliebs R, Weller R, Nicoll J, et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011 Apr 1;121(4):431–43. [PubMed]
Snorradottir AO, Isaksson HJ, Kaeser SA, Skodras AA, Olafsson E, Palsdottir A, et al. Deposition of collagen IV and aggrecan in leptomeningeal arteries of hereditary brain haemorrhage with amyloidosis. B [Internet]. 2013 Oct;1535:106–14. Available from: http://dx.doi.org/10.1016/j.brainres.2013.08.029
Wyss-Coray T, Lin C, Sanan D, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000 Jan 1;156(1):139–50. [PubMed]
Snorradottir A, Isaksson H, Ingthorsson S, Olafsson E, Palsdottir A, Bragason B. Pathological changes in basement membranes and dermal connective tissue of skin from patients with hereditary cystatin C amyloid angiopathy. Lab Invest. 2017 Apr 1;97(4):383–94. [PubMed]
Diem A, MacGregor S, Gatherer M, Bressloff N, Carare R, Richardson G. Arterial Pulsations cannot Drive Intramural Periarterial Drainage: Significance for <i>A</i>β Drainage. Front Neurosci. 2017 Aug 24;11:475. [PubMed]
Saito S, Ihara M. New therapeutic approaches for Alzheimer’s disease and cerebral amyloid angiopathy. Front Aging Neurosci. 2014 Oct 20;6:290. [PubMed]
Saito S, Kojima S, Oishi N, Kakuta R, Maki T, Yasuno F, et al. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol. Alzheimers Dement (N Y). 2016 Oct 27;2(4):250–7. [PMC]
Kitamura A, Manso Y, Duncombe J, Searcy J, Koudelka J, Binnie M, et al. Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion. Sci Rep. 2017 Jun 27;7(1):4299. [PubMed]
Yanai S, Ito H, Endo S. Long-term cilostazol administration prevents age-related decline of hippocampus-dependent memory in mice. Neuropharmacology. 2018 Feb 1;129:57–68. [PubMed]
Yanai S, Toyohara J, Ishiwata K, Ito H, Endo S. Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier. Neuropharmacology. 2017 Apr 1;116:247–59. [PubMed]
Maki T, Okamoto Y, Carare R, Hase Y, Hattori Y, Hawkes C, et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid. Ann Clin Transl Neurol. 2014 Jul 8;1(8):519–33. [PMC]
Manousopoulou A, Saito S, Yamamoto Y, Al-Daghri N, Ihara M, Carare R, et al. Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer’s Disease Mouse Model. J Alzheimers Dis. 2016 Mar 15;51(2):333–8. [PMC]
Bielicki J, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res. 2010 Jun 1;51(6):1496–503. [PubMed]
Narayan P, Orte A, Clarke R, Bolognesi B, Hook S, Ganzinger K, et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide. Nat Struct Mol Biol. 2011 Dec 18;19(1):79–83. [PubMed]
Wojtas AM, Kang SS, Olley BM, Gatherer M, Shinohara M, Lozano PA, et al. Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. P [Internet]. 2017 Jul 12;114(33):E6962–71. Available from: http://dx.doi.org/10.1073/pnas.1701137114
Saito S, Yamamoto Y, Maki T, Hattori Y, Ito H, Mizuno K, et al. Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy. Acta Neuropathol Commun. 2017 Apr 4;5:26. [PMC]
Katsouri L, Vizcaychipi M, McArthur S, Harrison I, Suárez-Calvet M, Lleo A, et al. Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer’s disease. Neurobiol Aging. 2013 Apr 1;34(4):1105–15. [PubMed]